NCT04132583View on ClinicalTrials.gov

Deflox Tablets Bioequivalence (BE) Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 21, 2019

Primary Completion Date

October 27, 2019

Study Completion Date

October 27, 2019

Conditions
Healthy
Interventions
DRUG

Deflox®

Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.

DRUG

Cataflam DD®

Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.

Trial Locations (1)

Unknown

Clinica de Enfermedades Crónicas y de Procedimientos Especiales S.C., Morelia

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04132583 - Deflox Tablets Bioequivalence (BE) Trial | Biotech Hunter | Biotech Hunter